XTX Topco Ltd Decreases Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

XTX Topco Ltd reduced its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 63.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,492 shares of the company's stock after selling 42,794 shares during the period. XTX Topco Ltd's holdings in Takeda Pharmaceutical were worth $324,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc acquired a new position in Takeda Pharmaceutical in the fourth quarter valued at about $26,000. Wilmington Savings Fund Society FSB acquired a new stake in Takeda Pharmaceutical in the 3rd quarter valued at approximately $40,000. Farther Finance Advisors LLC lifted its stake in Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter worth $52,000. Finally, Cromwell Holdings LLC purchased a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at $61,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.8 %

Takeda Pharmaceutical stock traded up $0.12 during mid-day trading on Monday, reaching $15.15. 938,229 shares of the company's stock were exchanged, compared to its average volume of 1,864,979. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37. The company has a market cap of $48.19 billion, a P/E ratio of 37.86, a P/E/G ratio of 0.24 and a beta of 0.39. The company has a fifty day moving average of $14.72 and a 200-day moving average of $13.93.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.